These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11304577)

  • 1. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma.
    Kang JH; Kim SJ; Noh DY; Park IA; Choe KJ; Yoo OJ; Kang HS
    Lab Invest; 2001 Apr; 81(4):573-9. PubMed ID: 11304577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter CpG island hypermethylation during breast cancer progression.
    Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
    Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
    Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
    Muggerud AA; Rønneberg JA; Wärnberg F; Botling J; Busato F; Jovanovic J; Solvang H; Bukholm I; Børresen-Dale AL; Kristensen VN; Sørlie T; Tost J
    Breast Cancer Res; 2010; 12(1):R3. PubMed ID: 20056007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
    Nass SJ; Herman JG; Gabrielson E; Iversen PW; Parl FF; Davidson NE; Graff JR
    Cancer Res; 2000 Aug; 60(16):4346-8. PubMed ID: 10969774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
    Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS
    J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer.
    Tommasi S; Karm DL; Wu X; Yen Y; Pfeifer GP
    Breast Cancer Res; 2009; 11(1):R14. PubMed ID: 19250546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Promoter methylation and mRNA expression of WT1 gene in MCF10 breast cancer model].
    Yang JL; Klinkebiel D; Boland MJ; Tang L; Christman JK
    Zhonghua Bing Li Xue Za Zhi; 2007 Apr; 36(4):253-8. PubMed ID: 17706117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of promoter hypermethylation in laser-microdissected archival specimens.
    Lehmann U; Hasemeier B; Lilischkis R; Kreipe H
    Lab Invest; 2001 Apr; 81(4):635-8. PubMed ID: 11304583
    [No Abstract]   [Full Text] [Related]  

  • 11. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
    Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
    Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
    Moelans CB; Verschuur-Maes AH; van Diest PJ
    J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression.
    Hoque MO; Prencipe M; Poeta ML; Barbano R; Valori VM; Copetti M; Gallo AP; Brait M; Maiello E; Apicella A; Rossiello R; Zito F; Stefania T; Paradiso A; Carella M; Dallapiccola B; Murgo R; Carosi I; Bisceglia M; Fazio VM; Sidransky D; Parrella P
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2694-700. PubMed ID: 19789364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer.
    Wang D; Li C; Zhang X
    DNA Cell Biol; 2014 Sep; 33(9):581-90. PubMed ID: 24842653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation.
    Pogribny IP; James SJ
    Cancer Lett; 2002 Feb; 176(2):169-74. PubMed ID: 11804744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
    Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
    Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Methylation status and protein expression of adenomatous polyposis coli (APC) gene in breast cancer].
    Liu Z; Yang L; Cui DX; Liu BL; Zhang XB; Ma WF; Zhang Q
    Ai Zheng; 2007 Jun; 26(6):586-90. PubMed ID: 17562262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.
    Fleischer T; Frigessi A; Johnson KC; Edvardsen H; Touleimat N; Klajic J; Riis ML; Haakensen VD; Wärnberg F; Naume B; Helland A; Børresen-Dale AL; Tost J; Christensen BC; Kristensen VN
    Genome Biol; 2014; 15(8):435. PubMed ID: 25146004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers.
    Zhang X; Sun Q; Shan M; Niu M; Liu T; Xia B; Liang X; Wei W; Sun S; Zhang Y; Liu XS; Song Q; Yang Y; Ma Y; Liu Y; Yang L; Ren Y; Zhang G; Pang D
    PLoS One; 2013; 8(1):e53931. PubMed ID: 23349767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.